What is it about?
This is a review paper summarizing the data on pembrolizumab and its use in non-small-cell lung cancer. Additionally, we have commented on the controversies behind PD-PDL1 bio-marker development and its many unknowns.
Featured Image
Read the Original
This page is a summary of: Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date, OncoTargets and Therapy, September 2016, Dove Medical Press,
DOI: 10.2147/ott.s97746.
You can read the full text:
Contributors
The following have contributed to this page
